Phase Ib, Multicenter, Open Label Study of PDR001 in Combination With Platinum-doublet Chemotherapy in PD-L1 Unselected, Metastatic NSCLC Patients

Trial Profile

Phase Ib, Multicenter, Open Label Study of PDR001 in Combination With Platinum-doublet Chemotherapy in PD-L1 Unselected, Metastatic NSCLC Patients

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Oct 2017

At a glance

  • Drugs PDR 001 (Primary) ; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ElevatION:NSCLC-101
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 15 Oct 2017 Trial design presented at the 18th World Conference on Lung Cancer.
    • 19 Jul 2017 Planned End Date changed from 23 Oct 2019 to 6 Nov 2019.
    • 19 Jul 2017 Planned primary completion date changed from 23 Oct 2019 to 6 Nov 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top